Health ❯ Healthcare ❯ Pharmaceuticals

Drug Approvals

FDA Approvals Eli Lilly Market Competition Lecanemab Pfizer Inc. Deflazacort Tablets Niacin Extended-Release Tablets NHS Spending Inluriyo Clinical Guidelines Wegovy Kisunla Revumenib Eylea HD Libtayo Approval Novo Nordisk Cancer Treatments Combination Therapies Vaping Targeted Therapies Pembrolizumab Belzutifan Belzutifan and Pembrolizumab Daraxonrasib Market Performance

10 ARTICLES

last mo.

FDA Expands Mounjaro Label to Include Cardiovascular Risk Reduction

Regulators cited a head-to-head trial that showed about an 8% relative drop in major heart events versus Lilly’s older drug Trulicity, prompting wider use for high-risk adults with type 2 diabetes.

8 ARTICLES

last mo.

FDA Approves Zanidatamab Regimens for First‑Line HER2‑Positive Gastroesophageal Cancer

3 ARTICLES

4mo ago

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

4 ARTICLES

4mo ago

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

3 ARTICLES

6mo ago

Pfizer’s Talzenna Plus Xtandi Delivers Phase 3 Win in Hormone-Sensitive Prostate Cancer

6 ARTICLES

9mo ago

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

3 ARTICLES

10mo ago

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

4 ARTICLES

10mo ago

FDA OKs RVO Use and Monthly Dosing for Regeneron’s Eylea HD

7 ARTICLES

last yr.

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC